We recently published a list of These 10 Stocks Blew Past Expectations. In this article, we are going to take a look at where ...

A French pharmaceutical giant is acquiring a biotech and its rare immunology disease treatment which is already approved in ...

Fintel reports that on June 4, 2025, Citigroup upgraded their outlook for Blueprint Medicines (NasdaqGS:BPMC) from Sell to ...

Fintel reports that on June 2, 2025, Wedbush downgraded their outlook for Blueprint Medicines (NasdaqGS:BPMC) from Outperform ...

Sanofi announced that it will buy pharma company Blueprint Medicines for $129 per share, making the deal worth more than $9 ...

The acquisition includes a rare immunology disease medicine and an advanced and early-stage immunology pipeline.

Stephens & Co. analyst Sudan Loganathan downgraded Blueprint Medicines Corporation (NASDAQ:BPMC) to Equal Weight from ...

Paris: Sanofi and Blueprint Medicines Corporation, a US-based, publicly traded biopharmaceutical company specializing in ...

Known as Enflonsia, the drug will compete for market share with Sanofi and AstraZeneca’s in-demand Beyfortus, which quickly ...

The stock, trading under the ticker (NASDAQ:BPMC), is a part of both the Nasdaq Biotechnology Index and the Nasdaq Today.

SNY, BMY, REGN and others ramp up 2025 dealmaking as pharma/biotech giants chase innovation across key growth areas.

Fintel reports that on June 4, 2025, Citigroup upgraded their outlook for Blueprint Medicines (NasdaqGS:BPMC) from Sell to Neutral. As of June 2, 2025, the average one-year price target for ...